These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 25285785)

  • 1. Could atomoxetine improve sluggish cognitive tempo symptoms?
    Yang R; Li R
    J Child Adolesc Psychopharmacol; 2014 Oct; 24(8):462. PubMed ID: 25285785
    [No Abstract]   [Full Text] [Related]  

  • 2. Cognitive enhancers for the treatment of ADHD.
    Bidwell LC; McClernon FJ; Kollins SH
    Pharmacol Biochem Behav; 2011 Aug; 99(2):262-74. PubMed ID: 21596055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Atomoxetine for the treatment of attention-deficit/hyperactivity disorder and oppositional defiant disorder.
    Bangs ME; Hazell P; Danckaerts M; Hoare P; Coghill DR; Wehmeier PM; Williams DW; Moore RJ; Levine L;
    Pediatrics; 2008 Feb; 121(2):e314-20. PubMed ID: 18245404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Focusing the Neuroscience and Societal Implications of Cognitive Enhancers.
    Savulich G; Piercy T; Brühl AB; Fox C; Suckling J; Rowe JB; O'Brien JT; Sahakian BJ
    Clin Pharmacol Ther; 2017 Feb; 101(2):170-172. PubMed ID: 27557349
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atomoxetine for attention deficit/hyperactivity disorder.
    Garces K
    Issues Emerg Health Technol; 2003 May; (46):1-4. PubMed ID: 12751480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, double-blind comparison of atomoxetine and placebo on response inhibition and interference control in children and adolescents with autism spectrum disorder and comorbid attention-deficit/hyperactivity disorder symptoms.
    van der Meer JM; Harfterkamp M; van de Loo-Neus G; Althaus M; de Ruiter SW; Donders AR; de Sonneville LM; Buitelaar JK; Hoekstra PJ; Rommelse NN
    J Clin Psychopharmacol; 2013 Dec; 33(6):824-7. PubMed ID: 24018545
    [No Abstract]   [Full Text] [Related]  

  • 7. A randomized double-blind study of atomoxetine versus placebo for attention-deficit/hyperactivity disorder symptoms in children with autism spectrum disorder.
    Harfterkamp M; van de Loo-Neus G; Minderaa RB; van der Gaag RJ; Escobar R; Schacht A; Pamulapati S; Buitelaar JK; Hoekstra PJ
    J Am Acad Child Adolesc Psychiatry; 2012 Jul; 51(7):733-41. PubMed ID: 22721596
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Atomoxetine in the treatment of attention deficit hyperactivity disorder.
    Kratochvil CJ; Vaughan BS; Daughton JM; Mayfield-Jorgensen ML; Burke WJ
    Expert Rev Neurother; 2004 Jul; 4(4):601-11. PubMed ID: 15853579
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Atomoxetine hydrochloride in the treatment of children and adolescents with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder: A placebo-controlled Italian study.
    Dell'Agnello G; Maschietto D; Bravaccio C; Calamoneri F; Masi G; Curatolo P; Besana D; Mancini F; Rossi A; Poole L; Escobar R; Zuddas A;
    Eur Neuropsychopharmacol; 2009 Nov; 19(11):822-34. PubMed ID: 19716683
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Should sluggish cognitive tempo symptoms be included in the diagnosis of attention-deficit/hyperactivity disorder?
    Todd RD; Rasmussen ER; Wood C; Levy F; Hay DA
    J Am Acad Child Adolesc Psychiatry; 2004 May; 43(5):588-97. PubMed ID: 15100565
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of atomoxetine on subjective and neurocognitive symptoms of nicotine abstinence.
    Ray R; Rukstalis M; Jepson C; Strasser A; Patterson F; Lynch K; Lerman C
    J Psychopharmacol; 2009 Mar; 23(2):168-76. PubMed ID: 18515446
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atomoxetine hydrochloride.
    Garland M; Kirkpatrick P
    Nat Rev Drug Discov; 2004 May; 3(5):385-6. PubMed ID: 15152632
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy of atomoxetine in children with severe autistic disorders and symptoms of ADHD: an open-label study.
    Charnsil C
    J Atten Disord; 2011 Nov; 15(8):684-9. PubMed ID: 20686100
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Atomoxetine in ADHD: caution].
    Karila L
    Rev Prat; 2011 Nov; 61(9 Suppl):S7-8. PubMed ID: 22338199
    [No Abstract]   [Full Text] [Related]  

  • 15. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H; Cherlin EA; Duesenberg DA; Bangs ME; Ramsey JL; Feldman PD; Allen AJ; Kelsey DK
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drugs under investigation for attention-deficit hyperactivity disorder.
    Schweitzer JB; Holcomb HH
    Curr Opin Investig Drugs; 2002 Aug; 3(8):1207-11. PubMed ID: 12211416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atomoxetine for encopresis in 2 children with attention-deficit/hyperactivity disorder.
    Hergüner S; Hergüner A
    J Clin Psychopharmacol; 2012 Apr; 32(2):302-3. PubMed ID: 22388168
    [No Abstract]   [Full Text] [Related]  

  • 18. Atomoxetine for attention deficit hyperactivity disorder in mental retardation.
    Fernández-Jaén A; Fernández-Mayoralas DM; Calleja Pérez B; Muñoz Jareño N; Campos Díaz Mdel R
    Pediatr Neurol; 2010 Nov; 43(5):341-7. PubMed ID: 20933178
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Atomoxetine: a new pharmacotherapeutic approach in the management of attention deficit/hyperactivity disorder.
    Barton J
    Arch Dis Child; 2005 Feb; 90 Suppl 1(Suppl 1):i26-9. PubMed ID: 15665154
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of atomoxetine on cardiovascular functions and on QT dispersion in children with attention deficit hyperactivity disorder.
    Sert A; Gokcen C; Aypar E; Odabas D
    Cardiol Young; 2012 Apr; 22(2):158-61. PubMed ID: 21864451
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.